Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Trading 07-07 12:58:46 EDT

11.60

+0.13

+1.13%

High11.85	Low11.25	Vol1.08M
Open11.61	D1 Closing11.47	Amplitude5.27%
Mkt Cap973.76M	Tradable Cap692.66M	Total Shares83.95M
T/O12.42M	T/O Rate1.80%	Tradable Shares59.71M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":11.6,"timestamp":1783443525024,"preClose":11.47,"halted":0,"volume":1076106,"delay":0,"changeRate":0.011333914559720925,"floatShares":59711800,"shares":83945161,"eps":-3.382838,"marketStatus":"Trading","change":0.13,"latestTime":"07-07 12:58:46 EDT","open":11.61,"high":11.85,"low":11.245,"amount":12420128.131698001,"amplitude":0.052746,"askPrice":11.61,"askSize":2,"bidPrice":11.59,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-3.382838,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1783454400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":11.47,"preHourTrading":{"tag":"盘前","latestPrice":11.5,"preClose":11.47,"latestTime":"09:25 EDT","volume":2473,"amount":28540.128843000002,"timestamp":1783430710028,"change":0.03,"changeRate":0.002616,"amplitude":0.00959},"postHourTrading":{"tag":"盘后","latestPrice":11.6,"preClose":11.47,"latestTime":"19:33 EDT","volume":10409,"amount":119688.512,"timestamp":1783380788295,"change":0.13,"changeRate":0.011334,"amplitude":0.030567},"volumeRatio":0.646924,"impliedVol":2.0172,"impliedVolPercentile":0.8526},"requestUrl":"/m/hq/s/REPL/","defaultTab":"news","newsList":[{"id":"2647593855","title":"Replimune Group is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2647593855","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647593855?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:01","pubTimestamp":1782824460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REPL/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 09:01 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553289","title":"Replimune price target raised to $9 from $6 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553289?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:50","pubTimestamp":1782820226,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Replimune (REPL) to $9 from $6 and keeps a Neutral rating on the shares. The firm notes the company repor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-price-target-raised-to-9-from-6-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-price-target-raised-to-9-from-6-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530859","title":"Replimune Group Inc : Bmo Raises to Outperform from Underperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530859","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530859?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:50","pubTimestamp":1782816651,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647303054","title":"Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2647303054","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647303054?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:55","pubTimestamp":1782748543,"startTime":"0","endTime":"0","summary":"Replimune (REPL) has an average rating of hold and mean price target of $7.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647330358","title":"Replimune Group put volume heavy and directionally bearish","url":"https://stock-news.laohu8.com/highlight/detail?id=2647330358","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647330358?lang=en_us&edition=fundamental","pubTime":"2026-06-29 23:15","pubTimestamp":1782746109,"startTime":"0","endTime":"0","summary":"Bearish flow noted in Replimune (REPL) Group with 1,899 puts trading, or 1.4x expected. Most active are Aug-26 7 puts and Aug-26 15 calls, with tot...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/replimune-group-put-volume-heavy-and-directionally-bearish-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647374518","title":"Replimune Group Q4 EPS $(0.76) Misses $(0.71) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2647374518","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647374518?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:52","pubTimestamp":1782737550,"startTime":"0","endTime":"0","summary":"Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.71) by 7.04 percent. This is a 7.32 percent increase over losses of $(0.82) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/60154266/replimune-group-q4-eps-0-76-misses-0-71-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647371279","title":"Replimune Group Inc Reports Results for the Quarter Ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2647371279","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647371279?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:37","pubTimestamp":1782736650,"startTime":"0","endTime":"0","summary":"Replimune Group Inc reports results for the quarter ended March 31 - Earnings SummaryReplimune Group IncREPL.OQreported a quarterly adjusted loss of 76 cents per share for the quarter ended March 31, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nL8N4310ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647437160","title":"Replimune's Fiscal Q4 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2647437160","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647437160?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:27","pubTimestamp":1782736058,"startTime":"0","endTime":"0","summary":"Replimune Group  reported a fiscal Q4 net loss Wednesday of $73.7 million, narrowing from a net loss of $74.1 million a year earlier.Analysts polled by FactSet expected a net loss of $63.9 million.As of March 31, the company said it had $268.9 million in cash, cash equivalents and short-term investments, which it said will fund operations into Q1 2027.Shares of the company were down 2.8% in Monday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647777379","title":"Earnings Flash (REPL) Replimune Posts Fiscal 2026 Net Loss $3.38 a Share, vs. FactSet Est of $3.27 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2647777379","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647777379?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:09","pubTimestamp":1782734963,"startTime":"0","endTime":"0","summary":"Earnings Flash (REPL) Replimune Posts Fiscal 2026 Net Loss $3.38 a Share, vs. FactSet Est of $3.27 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647293379","title":"Replimune FY26 Net Loss Widens to $313.94 Million; R&D Expenses Rise to $221.18 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2647293379","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647293379?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:03","pubTimestamp":1782734609,"startTime":"0","endTime":"0","summary":"Replimune FY26 net loss widens to $313.94 million; R&D expenses rise to $221.18 millionReplimune fiscal year ended March 31, 2026 net loss widened to USD 313.94 million; loss per share widened to USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL2hqk3p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","NDAQ","SG9999014013.SGD","BK4588","BK4139","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","BK4585","SG9999014005.SGD","BK4112","LU2210149790.SGD","SG9999014021.USD","REPL","SG9999014039.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379654","title":"Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379654?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:00","pubTimestamp":1782734403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nTUA930WZ4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379100","title":"Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379100","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647379100?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:50","pubTimestamp":1782733832,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Replimune Group (REPL) and Monopar Therapeutics Inc (MNPR). Repli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-replimune-group-repl-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-replimune-group-repl-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","XBI","HCSG","REPL","BK4581","LABU","MNPR","BK4588","BK4137","BK4585","LU0128526141.USD","XLV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646702366","title":"Replimune Group Inc : JP Morgan Raises to Overweight from Neutral; Raises Target Price to $17 from $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2646702366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646702366?lang=en_us&edition=fundamental","pubTime":"2026-06-26 23:28","pubTimestamp":1782487687,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42Y0VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646350431","title":"Replimune Slips as FDA Accepts Skin Cancer Drug Review, but Advisory Panel Adds Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2646350431","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646350431?lang=en_us&edition=fundamental","pubTime":"2026-06-26 21:17","pubTimestamp":1782479878,"startTime":"0","endTime":"0","summary":"BUZZ-Replimune slips as FDA accepts skin cancer drug review, but advisory panel adds risk** Shares of ReplimuneREPL.Ofall 4.7% to $10.61 premarket** Replimune says the U.S. FDA has accepted co's resub","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nL4N42Y0UP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0432979614.USD","LU1868837136.USD","LU1868837300.USD","BK4588","LU0096364046.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","LU1868836914.USD","LU1430594728.SGD","LU1571399168.USD","LU0868494617.USD","LU2360032135.SGD","LU1883839398.USD","LU2133065610.SGD","IE00B2B36J28.USD","LU2125154778.USD","BK4007","BMY","LU2125154935.USD","LU0114720955.EUR","LU0225284248.USD","LU1323610961.USD","LU1670710661.SGD","LU2242652126.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","LU1670711123.USD","LU1670711040.USD","IE00BFTCPJ56.SGD","LU1093756168.USD","BK4532","LU0061475181.USD","LU0985481810.HKD","LU0225771236.USD","LU1074936037.SGD","REPL","LU0267386448.USD","IE00BFXG1179.USD","LU0882574055.USD","BK4581","IE0002141913.USD","LU1983299246.USD","LU1718418525.SGD","LU0306806265.USD","LU1032466523.USD","LU0237698245.USD","BK4534","LU2596442595.SGD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646235252","title":"Replimune Says FDA Accepts RP1 Melanoma BLA Resubmission for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2646235252","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646235252?lang=en_us&edition=fundamental","pubTime":"2026-06-26 20:01","pubTimestamp":1782475267,"startTime":"0","endTime":"0","summary":"Replimune says FDA accepts RP1 melanoma BLA resubmission for reviewReplimune’s FDA accepted for review the resubmitted BLA for RP1 with nivolumab in advanced melanoma.Agency classified the filing as a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLsmYyH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210150020.SGD","BK4139","IE00BN0W2T93.GBP","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646525563","title":"Replimune Group - FDA Sets August 2, 2026 Goal Date for Rp1 Bla Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2646525563","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646525563?lang=en_us&edition=fundamental","pubTime":"2026-06-26 20:00","pubTimestamp":1782475200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nTUA4XW62Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646523973","title":"Replimune Announces FDA Acceptance of Rp1 Biologics License Application Resubmission for Advanced Melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2646523973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646523973?lang=en_us&edition=fundamental","pubTime":"2026-06-26 20:00","pubTimestamp":1782475200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nTUA4XW62Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646876915","title":"U.S. Earnings Preview: Before Market Open June 25","url":"https://stock-news.laohu8.com/highlight/detail?id=2646876915","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646876915?lang=en_us&edition=fundamental","pubTime":"2026-06-25 17:31","pubTimestamp":1782379860,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results before the mark","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00B4QBRK32.GBP","BK4209","LU2237443895.HKD","LU1363072403.SGD","LU2237443978.SGD","BK4006","DRI","LU0048573561.USD","BK4139","IE00BHPRN162.USD","BK4099","BK4212","LU0154245756.USD","CMC","LU2746668461.USD","LU2237443382.USD","IE00BZ1G4Q59.USD","REPL","LU0971096721.USD","IE00B1BXHZ80.USD","LU0882574139.USD","LU0690374615.EUR","MKC","LU0170899867.USD","BK4597","IE00BFXG1179.USD","BK4585","BK4504","LU0345770308.USD","LU0742534661.SGD","LU0345770993.USD","LU2404859667.USD","LU0149725797.USD","LU0251131958.USD","LU2237443549.SGD","GB00B4LPDJ14.GBP","LU2237443465.HKD","LU2404859741.USD","BK4588","WGO","BK4140","LU0267386448.USD","LU2746668974.SGD","LU0690374961.EUR","IE00BKVL7J92.USD","LU2237443622.USD","LU0154245673.USD","LU0251142724.SGD","SNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644054015","title":"QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2644054015","media":"InvestorPlace","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644054015?lang=en_us&edition=fundamental","pubTime":"2026-06-19 20:24","pubTimestamp":1781871896,"startTime":"0","endTime":"0","summary":"https://www.youtube.com/live/nFu_fTQv1_Q Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open.  UniQure NV…","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"investorplace_stock_picks","url":"https://investorplace.com/dailylive/2026/06/qure-was-just-the-beginning-5-biotech-catalysts-to-watch/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://investorplace.com/dailylive/2026/06/qure-was-just-the-beginning-5-biotech-catalysts-to-watch/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investorplace_stock_picks","symbols":["BK4139","CELC","BK4585","IONS","QURE","LU0320765992.SGD","REPL","LABU","LU0109394709.USD","TVTX","BK4588","XBI","LU0889565916.HKD","BK4581","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644517410","title":"Replimune Group Inc  expected to post a loss of 71 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2644517410","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644517410?lang=en_us&edition=fundamental","pubTime":"2026-06-19 19:05","pubTimestamp":1781867112,"startTime":"0","endTime":"0","summary":"Replimune Group Inc  expected to post a loss of71cents a share - Earnings Preview Replimune Group Inc REPL.OQ REPL.O is expected to  show no change in quarterly revenue when it reports  results on Jun","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260619:nL8N42R0N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com;ir.replimune.com","stockEarnings":[{"period":"1week","weight":0.0241},{"period":"1month","weight":0.2112},{"period":"3month","weight":0.4705},{"period":"6month","weight":0.2859},{"period":"1year","weight":0.2202},{"period":"ytd","weight":0.18}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":0.0186},{"period":"3month","weight":0.1396},{"period":"6month","weight":0.0895},{"period":"1year","weight":0.2014},{"period":"ytd","weight":0.1017}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.050762},{"month":3,"riseRate":0.25,"avgChangeRate":-0.088086},{"month":4,"riseRate":0.5,"avgChangeRate":0.020849},{"month":5,"riseRate":0.5,"avgChangeRate":0.255044},{"month":6,"riseRate":0.875,"avgChangeRate":0.229422},{"month":7,"riseRate":0.375,"avgChangeRate":-0.072865},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}